HK Stock Market Move | Nuclear power stocks saw their morning gains expand, with CNNC INT'L (02302) rising nearly 12% midday. Microsoft and Nvidia reached a cooperation agreement in the nuclear energy sector for AI.
Nuclear power concept stocks saw a further increase in the morning, as of the time of writing, CNNC International (02302) rose by 9.61% to HKD 6.5; CGN Power (01816) rose by 5.08% to HKD 3.72; CGN Mining (01164) rose by 4.57% to HKD 3.89.
Nuclear concept stocks saw expanded gains in the morning session, as of press time, CNNC INT'L (02302) rose 9.61% to HK$6.5; CGN POWER (01816) rose 5.08% to HK$3.72; CGN MINING (01164) rose 4.57% to HK$3.89.
On the news front, Microsoft and Nvidia announced a partnership to advance the "AI for nuclear" program, aiming to accelerate the construction and operation of nuclear power plants with the help of artificial intelligence tools to meet the huge energy demand brought by the rapid expansion of the AI industry. Microsoft Vice Chairman and President Brad Smith publicly announced the cooperation at the CERAWeek energy conference on Tuesday. He stated that the two companies have truly created a set of solutions that are expected to play an important role in promoting the expansion of nuclear power construction.
CMSC pointed out that the price differential contract model in Liaoning and Guangxi provides a guarantee mechanism for nuclear power, allowing most of the electricity generated by nuclear power plants to be settled at approved prices. In order to avoid the profitability of nuclear power being greatly affected by market fluctuations, other provinces are also expected to introduce similar electricity price guarantee mechanisms to ensure the safe and stable operation of nuclear power plants. The profitability stability of nuclear power enterprises will be further enhanced, coupled with the high growth brought by the gradual commissioning of nuclear power units, the valuation of nuclear power enterprises is expected to be reshaped.
Related Articles

BAO PHARMA-B (02659): The follow-up of Phase III clinical trial for kidney transplant desensitization treatment with KJ103 has been completed.

BIOSTAR PHARM-B(02563): Expected audit reservation opinion

MNSO (09896) spent $228,500 on March 24 to buy back 55,600 shares.
BAO PHARMA-B (02659): The follow-up of Phase III clinical trial for kidney transplant desensitization treatment with KJ103 has been completed.

BIOSTAR PHARM-B(02563): Expected audit reservation opinion

MNSO (09896) spent $228,500 on March 24 to buy back 55,600 shares.

RECOMMEND

Pace Of Public Fund Issuance Slows, Hong Kong Stocks Become A Primary Focus
24/03/2026

Jensen Huang In‑Depth Interview: Token Economy Surge, AI Computing’s Share Of GDP To Multiply One Hundredfold, NVIDIA’s $10 Trillion Valuation Inevitable
24/03/2026

Are U.S.‑Iran Talks Genuine? At Minimum, Wall Street Read A Clear Signal From Trump’s Five‑Minute Rally
24/03/2026


